key: cord-0773529-0faody3x authors: Riley, Christopher J.; Teixeira, Pedro title: Development of symptomatic inflammatory aneurysm treated with endovascular repair in COVID-19 infected patient date: 2021-03-23 journal: J Vasc Surg Cases Innov Tech DOI: 10.1016/j.jvscit.2021.03.003 sha: 41afb1dcb7446a80a953a8014670277333df2570 doc_id: 773529 cord_uid: 0faody3x Sequelae and complications of COVID-19 infection continue to emerge during this pandemic era. While long term effects are continually being monitored and studied, we are seeing more acute and subacute medical complications requiring thorough discussion and sometimes adjustment of our standard care and intervention. In this report, we describe a case of an acute, symptomatic inflammatory vs mycotic abdominal aortic aneurysm in a COVID-19 positive patient undergoing urgent endovascular repair. Authorship Responsibility and Contributions to Authorship. The authors must use the contributions table to indicate their involvement in the creation of this manuscript. It is important that a box is checked in each authorship category, otherwise the person will not qualify for authorship and the manuscript will be returned to the authors for correction. The boxes for "Approval" and Accountability" must be checked for ALL authors. If an author declines to approve or be accountable for the work, they may not be included as authors. CRITERIA REQUIRED FOR AUTHORSHIP. Authors must have contributed in all four categories. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved List 2 initials for each author (example: AS, BP). In the case of two authors with the same initials, please use their middle initial to differentiate between them (example: JEB, JTB). Overall responsibility. Christopher J Riley assumes overall responsibility and guarantees the scientific integrity of the work as a whole. ☐ ☐ ☐ ☐ SHARED FIRST AUTHORSHIP: Check this box if two authors participated equally and should share "first authorship". List these as first and second authors. If two authors participated equally and should share "senior authorship" enter their initials here: EACH author must disclose all relevant financial and nonfinancial potential conflicts of interest with respect to this manuscript. Potential conflicts of interest include, but are not limited to: 1. A financial contribution to the author or the authors' institution from a company or organization that might benefit (or lose) financially from the results, conclusions or discussion presented in the manuscript Examples include: Royalties, Patents (or patents pending), fees for consulting, fees for speaking when organized by a corporate sponsored speakers' bureau, funds for a member of the author's staff or family 2. Ownership of stocks, shares or options in a company or organization that might benefit (or lose) financially from the results, conclusion or discussion presented in the paper/letter 3. A commercial interest in the form of a relationship with an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients 4. Other potential conflicts include: a. an academic association or antagonism with someone whose interest might be affected by the paper b. membership in a special interest group whose interests might be affected by the paper c. other strong convictions that might have affected what was written List conflicts of interest for EACH author below. If there are no conflicts of interest, please state "The authors have no competing interests" in the space below. Each author must disclose the name and involvement of all entities that provided financial support for this work. Please list the funding (grant, scholarships, donated devices, etc.) and describe the involvement of each sponsor in the: 1.Study design; collection, analysis, and interpretation of data; 2.Manuscript writing 3. The decision to submit the manuscript for publication 4. Any other involvement in the creation of the manuscript (Artwork, critical revision, etc.) The authors must make a meaningful disclosure regarding their discussions of off label or unapproved drugs or devices. ☐ This study does include off label drugs and/or devices. The specific names of the products discussed are: Click or tap here to enter text. ☒ This study does not include off label drugs and/or devices. Example: This work was funded by corporation XYZ. Corporation XYZ had no involvement in the study design or collection, analysis, and interpretation of data. Corporation XYZ paid for a professional editor to assist with writing the manuscript. Corporation XYZ was not involved in the decision to submit the manuscript for publication. The corresponding author confirms that they and the co-authors believe that this form and all accompanying files describe truthful facts. The corresponding author also certifies that they and each co-author have participated to a sufficient degree to take public responsibility for this manuscript, that their contributions and relevant conflicts of interest are accurately and completely reported on this form. total aortic aneurysmal incidence. [3] [4] [5] These types are associated with periaortic inflammation not 10 noted in atherosclerotic aneurysm disease. 5 The patient was in agreement to the publication of 11 this report. Given her worsening clinical physical exam, evidence of increasing inflammatory findings and 10 concern for risk of rupture in the setting of hemodynamic stability, decision was made to proceed 11 with Endovascular Aneurysm Repair (EVAR). Of note, her COVID-19 illness was treated with 12 Hydroxychloroquine for 5 days, which was completed 4 days prior to EVAR. Aortic stent was noted to be positioned appropriately, without evidence of an endoleak ( Figure 7 3). Previously noted inflammatory findings had resolved. On exam, she had completely 8 recovered from her COVID-19 pulmonary symptoms and had no abdominal or flank pain. As the multi-system complications and sequelae resulting from COVID-19 infection continue to 12 be discovered, the approach to evaluating and managing both emergent and non-emergent The progression of the clinical symptoms and risk of rupture was the main factor for urgent 3 repair in this patient. Whether the inflammatory etiology is a mechanism of the active COVID-4 19 infection or pre-existing factors remains unknown. As we continue to gather reports and data, 5 and progressively learn about this novel virus, it is important that we maintain optimal care and 6 availability of surgical interventions while also minimizing patient complication risk and COVID-19): A Systematic Review And Meta-Analysis Coronaviruses On The Cardiovascular System Mycotic Or Infected Aneurysm? Time To Change The 9 Inflammatory Abdominal Aortic Aneurysm Doing The Right Thing For The Right Reason 19 When Treating Ruptured Abdominal Aortic Aneurysms In The COVID-19 Era Inflammatory Abdominal Aortic Aneurysm: Report Of Seven Cases The Society For Vascular Surgery Practice Guidelines On The Care Of Patients With An 6 Endovascular Repair Of 9 Abdominal Aortic Aneurysms: Outcome And Predictors Analysis Inflammatory Aneurysm Of The Thoracic Aorta Endovascular Treatment Of A Ruptured Pararenal 19 Endovascular Repair In A Patient With Active COVID-19 Infection During The 2 Pandemic Endovascular management 5 of ruptured common iliac mycotic aneurysm in an HIV-positive patient Pathogenetic profiling 8 of COVID-19 and SARS-like viruses STAT3-induced up-regulation 11 of lncRNA NEAT1 as a ceRNA facilitates abdominal aortic aneurysm formation by 12 elevating TULP3